• Explore /
  • Poster
  • / Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

Abstract Poster

Authors

null

Abhishek Avinash Mangaonkar

Division of Hematology, Mayo Clinic, Rochester, MN

Abhishek Avinash Mangaonkar , Cecilia Ysabel Arana Yi , Hemant S. Murthy , Talha Badar , James M. Foran , Susan Michelle Geyer , Kristen Beth McCullough , Jean Hanson , Aref Al-Kali , Hassan B. Alkhateeb , Mithun Vinod Shah , Kebede Begna , Michelle A. Elliott , Naseema Gangat , Mark Robert Litzow , Alexandra P. Wolanskyj-Spinner , William J. Hogan , Ayalew Tefferi , Mrinal Patnaik , Erinayo S Baba Lola

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Other Leukemia, Myelodysplastic Syndromes, and Allotransplant

Clinical Trial Registration Number

NCT05005182

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7080)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7080

Abstract #

TPS7080

Poster Bd #

302a

Abstract Disclosures

Similar Posters

First Author: Jie Liu

First Author: Steven Gilmore

First Author: Cyrille Touzeau

First Author: Francis Guerra-Bauman